Inflammatory molecules: A target for treatment of systemic autoimmune diseases

Autoimmunity Reviews

Volumn 7, Issue 1, 2007, Pages 1-7

  Tincani, A ^a   Andreoli, L ^a   Bazzani, C ^a   Bosiso, D ^a   Sozzani, S ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Biological therapies; Chemokines; Inflammation; Rheumatoid Arthritis; Systemic Lupus Erythematosus

Indexed keywords

ABATACEPT; ABETIMUS; ADALIMUMAB; AMG 108; ATLIZUMAB; BELIMUMAB; CHEMOKINE; CYTOKINE; DNA ANTIBODY; ECULIZUMAB; EDRATIDE; EPRATUZUMAB; ETANERCEPT; IMMUNOGLOBULIN G1 ANTIBODY; INFLIXIMAB; INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 6 ANTIBODY; LYMPHOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AMG 108; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SELECTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATION; MACROPHAGE; MEDIATOR; MOLECULAR EVOLUTION; MONOTHERAPY; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35448943946     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2007.03.001     Document Type: Review

References (33)

1. Mantovani A., Locati M., Vecchi A., Sozzani S., and Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 22 (2001) 328-336
2. Schmid-Schonbein G.W. Analysis of inflammation. Annu Rev Biomed Eng 8 (2006) 93-131
3. Schwab J.M., and Serhan C.N. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 6 (2006) 414-420
4. Del Prete A., Locati M., Otero K., Riboldi E., Mantovani A., Vecchi A., et al. Migration of dendritic cells across blood and lymphatic endothelial barriers. Thromb Haemost 95 (2006) 22-28
5. Rot A., and von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokines grammar for immune cells. Annu Rev Immunol 22 (2004) 891-928
6. Mantovani A., Bonecchi R., and Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 6 (2006) 907-918
7. Locati M., Allavena P., Sozzani S., and Mantovani A. Shaping and tuning of the chemokine system by regulation of receptor expression and signaling: dendritic cells as a paradigm. J Neuroimmunol 107 (2000) 174-177
8. Del Prete A., Shao W.H., Mitola S., Santoro G., Sozzani S., and Haribabu B. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood 109 (2007) 626-631
9. Locati M., Zhou D., Luini W., Evangelista V., Mantovani A., and Sozzani S. Rapid induction of arachidonic acid release by monocyte chemotactic protein-1 and related chemokines. Role of Ca2+ influx, synergism with platelet-activating factor and significance for chemotaxis. J Biol Chem 269 (1994) 4746-4753
10. Sozzani S. Dendritic cell trafficking: more than just chemokines. Cytokine Growth Factor Rev 16 (2005) 581-592
11. Banchereau J., and Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25 (2006) 383-392
12. Vermi W., Riboldi E., Wittamer V., Gentili F., Luini W., Marrelli S., et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med 201 (2005) 509-515
13. Wittamer V., Franssen J.D., Vulcano M., Mirjolet J.F., Le Poul E., Migeotte I., et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 198 (2003) 977-985
14. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
15. Feldmann M., Brennan F.M., Foxwell B.M., Taylor P.C., Williams R.O., and Maini R.N. Anti-TNF therapy: where have we got to in 2005?. J Autoimmun 25 Suppl (2005) 26-28
16. Feldmann M., Elliott M.J., Woody J.N., and Maini R.N. Antitumour necrosis factor α therapy of rheumatoid arthritis. Adv Immunol 64 (1997) 283-350
17. Feldmann M., Bondeson J., Brennan F.M., Foxwell B.M.J., and Maini R.N. The rationale for the current boom in anti-TNFα treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFá and minimise hazards?. Ann Rheum Dis 58 Suppl I (1999) I27-I31
18. Williams RO, Feldmann M, and Maini RN. Anti-Tumor Necrosis Factor Ameliorates Joint Disease in Murine Collagen-Induced Arthritis. PNAS 89 (20): 9784.
19. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arth Rheum 36 12 (1993) 1681-1690
20. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
21. Mok C.C., and Lau C.S. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56 (2003) 481-490
22. Song W.-C. Complement regulatory proteins and autoimmunity. Autoimmunity 39 (2006) 403-410
23. Isenberg D., and Rahman A. Systemic lupus erythematosus - 2005 annus mirabilis?. Nat Clin Pract Rheumatol 2 (2006) 145-152
24. Vasoo S., and Hughes G.R.V. Theory, targets and therapy in systemic lupus erythematosus. Lupus 14 (2005) 181-188
25. Eisenberg R., and Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2 (2006) 20-27
26. Daikh D., and Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4-Ig and cyclophosphamide. J Immunol 166 (2001) 2913-2916
27. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 (2003) 719-727
28. Kalunian K.C., Davis Jr. J.C., Merrill J.T., Totoritis M.C., Wofsy D., and IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 3251-3258
29. Merrill J.T. BLyS antagonists and peptide tolerance induction. Lupus 14 (2005) 204-209
30. Alarcon-Segovia D., Tumlin J.A., Furie R.A., et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum 48 (2003) 442-454
31. Llorente L., Richard-Patin Y., Garcia-Padilla C., et al. Clinical and biologic effects of anti-interleukin 10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43 (2000) 1790-1800
32. Shirota Y., Yarboro C., Sims G., Fritsch R., Ettinger R., Valencia X., et al. The Impact of In Vivo Anti IL-6 Receptor Blockade on Circulating T and B Cell Subsets in Patients with Systemic Lupus Erythematosus. Arthritis Rheum 52 (2005) S697
33. Rother R.P., Mojcik C.F., and McCroskery E.W. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 13 (2004) 328-334